Physician profile
Christina Schultz
NPI 1104801661
$1,929.39
in general payments reported to CMS, 2019-2025
19 companies · $40.95 in 2025
The $40.95 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $126 · 2023: $1,116 · 2024: $420 · 2025: $40.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.79 |
| Education | $176.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $287.43 | 2023-2024 | Uzedy, Austedo Xr |
| Abbvie INC. | $217.85 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.60 | 2021-2023 | |
| Alkermes, INC. | $206.59 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $205.87 | 2022-2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $147.99 | 2021-2025 | Abilify Asimtufii, Nuedexta, Rexulti |
| Indivior INC. | $146.91 | 2023-2024 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $128.00 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $79.07 | 2021 | |
| Gilead Sciences, INC. | $69.24 | 2023 | Epclusa |
| Janssen Pharmaceuticals, INC | $41.82 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $40.96 | 2022 | |
| Bausch Health US, LLC | $36.41 | 2021 | |
| Vanda Pharmaceuticals INC. | $28.29 | 2023 | Fanapt, Hetlioz |
| Hikma Pharmaceuticals USA | $21.00 | 2023 | Kloxxado |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $15.23 | 2023 | Zubsolv |
| Noven Therapeutics, LLC | $14.96 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.33 | 2021 | |
| Lundbeck LLC | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.